Unum Therapeutics Inc (UMRX) Expected to Announce Earnings of -$0.35 Per Share

Wall Street analysts expect Unum Therapeutics Inc (NASDAQ:UMRX) to report earnings of ($0.35) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Unum Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.33) and the lowest estimate coming in at ($0.37). The business is scheduled to issue its next quarterly earnings results on Monday, February 11th.

According to Zacks, analysts expect that Unum Therapeutics will report full-year earnings of ($1.56) per share for the current financial year, with EPS estimates ranging from ($1.67) to ($1.44). For the next year, analysts anticipate that the company will post earnings of ($1.50) per share, with EPS estimates ranging from ($1.59) to ($1.42). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Unum Therapeutics.

Unum Therapeutics (NASDAQ:UMRX) last announced its earnings results on Monday, November 12th. The company reported ($0.34) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.01. Unum Therapeutics had a negative net margin of 404.34% and a negative return on equity of 382.71%. The company had revenue of $2.04 million for the quarter, compared to analysts’ expectations of $2.29 million.

Several research analysts have recently commented on UMRX shares. Cowen reaffirmed a “hold” rating on shares of Unum Therapeutics in a report on Monday, November 19th. Zacks Investment Research raised shares of Unum Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, November 6th. Wedbush lifted their price objective on shares of Unum Therapeutics from $18.00 to $20.00 and gave the company an “outperform” rating in a research note on Tuesday, August 14th. Finally, Morgan Stanley lifted their price objective on shares of Unum Therapeutics from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Thursday, October 11th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $20.67.

In related news, insider Seth Ettenberg sold 11,485 shares of Unum Therapeutics stock in a transaction that occurred on Thursday, October 25th. The shares were sold at an average price of $8.46, for a total value of $97,163.10. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold 34,455 shares of company stock worth $320,776 over the last three months.

A number of large investors have recently made changes to their positions in UMRX. Millennium Management LLC bought a new position in Unum Therapeutics in the first quarter valued at approximately $982,000. Jennison Associates LLC boosted its position in Unum Therapeutics by 4.3% in the second quarter. Jennison Associates LLC now owns 935,307 shares of the company’s stock valued at $13,305,000 after buying an additional 38,552 shares in the last quarter. Wasatch Advisors Inc. boosted its position in Unum Therapeutics by 5.3% in the second quarter. Wasatch Advisors Inc. now owns 267,625 shares of the company’s stock valued at $3,840,000 after buying an additional 13,525 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Unum Therapeutics in the second quarter valued at approximately $177,000. Finally, Spark Investment Management LLC acquired a new stake in Unum Therapeutics in the second quarter valued at approximately $186,000. 51.81% of the stock is currently owned by institutional investors and hedge funds.

Shares of UMRX opened at $6.90 on Thursday. Unum Therapeutics has a 12 month low of $6.26 and a 12 month high of $17.66.

About Unum Therapeutics

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.

Recommended Story: What is a Leveraged Buyout (LBO)?

Get a free copy of the Zacks research report on Unum Therapeutics (UMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Unum Therapeutics (NASDAQ:UMRX)

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit